Eagle Pharmaceuticals Inc
NASDAQ:EGRX
Eagle Pharmaceuticals Inc
Cash from Investing Activities
Eagle Pharmaceuticals Inc
Cash from Investing Activities Peer Comparison
Competitive Cash from Investing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Eagle Pharmaceuticals Inc
NASDAQ:EGRX
|
Cash from Investing Activities
-$23.8m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-41%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Investing Activities
-$2B
|
CAGR 3-Years
62%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Investing Activities
-$2.3B
|
CAGR 3-Years
48%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-76%
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Investing Activities
-$26.2B
|
CAGR 3-Years
-69%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-12%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Investing Activities
-$3.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-73%
|
CAGR 10-Years
-50%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Investing Activities
-$3.2B
|
CAGR 3-Years
-256%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-25%
|
See Also
What is Eagle Pharmaceuticals Inc's Cash from Investing Activities?
Cash from Investing Activities
-23.8m
USD
Based on the financial report for Jun 30, 2023, Eagle Pharmaceuticals Inc's Cash from Investing Activities amounts to -23.8m USD.
What is Eagle Pharmaceuticals Inc's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 5Y
-41%
Over the last year, the Cash from Investing Activities growth was 69%. The average annual Cash from Investing Activities growth rates for Eagle Pharmaceuticals Inc have been -9% over the past three years , -41% over the past five years .